A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
The FDA has approved oveporexton, marketed as Orzeyful, a first-in-class orexin agonist designed to treat narcolepsy type 1. Data from Phase 3 studies published in the New England Journal of Medicine show the drug improves quality of life and the full range of symptoms associated with the disorder. Takeda announced the publication of this study data, which supports the drug's ability to reduce the sleepiness fog experienced by patients. The medication has also secured global approvals to provide a new treatment option for those living with the sleep disorder.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA approved oveporexton for the treatment of narcolepsy.
- ✓ Oveporexton is marketed under the brand name Orzeyful.
- ✓ Phase 3 study data published in the New England Journal of Medicine indicates oveporexton improves quality of life and the full range of narcolepsy type 1 symptoms.
- ✓ Oveporexton is a first-in-class orexin agonist.
What changed
The FDA and global regulators approved oveporexton after Phase 3 clinical data demonstrated symptom improvement.
Live updates
-
FDA Approves Oveporexton for Narcolepsy Type 1 Treatment
The FDA has approved oveporexton, marketed as Orzeyful, a first-in-class orexin agonist designed to treat narcolepsy type 1. Data from Phase 3 studies published in the New England Journal of Medicine show the drug improves quality of life and the full range of symptoms associated with the disorder. Takeda announced the publication of this study data, which supports the drug's ability to reduce the sleepiness fog experienced by patients. The medication has also secured global approvals to provide a new treatment option for those living with the sleep disorder.
Why it matters
Narcolepsy type 1 is a chronic sleep disorder characterized by excessive daytime sleepiness. Previous treatments often managed symptoms without targeting the underlying orexin deficiency. This new class of drug specifically targets orexin receptors to regulate wakefulness.
What is confirmed
- The FDA approved oveporexton for the treatment of narcolepsy.
- Oveporexton is marketed under the brand name Orzeyful.
- Phase 3 study data published in the New England Journal of Medicine indicates oveporexton improves quality of life and the full range of narcolepsy type 1 symptoms.
- Oveporexton is a first-in-class orexin agonist.
- Takeda announced the publication of the Phase 3 study data.
What to watch next
- Availability dates for Orzeyful in various global markets
- Long-term safety data following widespread clinical adoption
confidence 100%Sources used for this update (8)
- The New York Times — A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
- WJAR — Breakthrough drug to treat narcolepsy gains FDA approval
- BioSpace — New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
- Psychiatric Times — New Phase 3 Data on Oveporexton for Narcolepsy Type 1
- Sleep Review — First-in-Class Orexin Agonist Secures Global Approvals for Narcolepsy Type 1
- TipRanks — Takeda announces publication of data from Phase 3 studies of oveporexton
- facebook.com — A first-of-its-kind drug for narcolepsy was approved by the FDA, offering a new treatment for people who live with the sleep disorder.
- medicalxpress.com — 'Power naps' may improve clinical performance for sleep-deprived anesthesiology residents
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community